DCPG ((S)-3,4-DCPG) is a drug used in scientific research, which acts as a potent and subtype-selective agonist for the metabotropic glutamate receptor mGluR8. It has anticonvulsant effects in animal studies,[1][2] and has also been investigated as a possible treatment for hyperalgesia.[3]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.161.870 |
| Chemical and physical data | |
| Formula | C10H9NO6 |
| Molar mass | 239.183 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
References
edit- ^ Moldrich RX, Chapman AG, De Sarro G, Meldrum BS (August 2003). "Glutamate metabotropic receptors as targets for drug therapy in epilepsy". European Journal of Pharmacology. 476 (1–2): 3–16. doi:10.1016/s0014-2999(03)02149-6. PMID 12969743.
- ^ Folbergrová J, Druga R, Haugvicová R, Mares P, Otáhal J (March 2008). "Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid". Neuropharmacology. 54 (4): 665–75. doi:10.1016/j.neuropharm.2007.11.015. PMID 18191956. S2CID 20697899.
- ^ Marabese I, de Novellis V, Palazzo E, Scafuro MA, Vita D, Rossi F, Maione S (February 2007). "Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice". Neuropharmacology. 52 (2): 253–62. doi:10.1016/j.neuropharm.2006.04.006. PMID 17113112. S2CID 25646746.
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |